Meta description: Global and North American MedTech M&A deal activity rises after 2023 slowdown, with strategic and private equity buyers focusing on high-growth segments.
Healthcare and MedTech mergers and acquisitions are showing a strong rebound after a sharp slowdown in 2023. The latest 24-month analysis indicates rising deal flow, changing valuation multiples, and heightened participation from both corporate strategics and private equity firms. Founders, corporate development teams, and investors will find the recent data useful for timing transactions and identifying high-demand subsectors.
- What is driving the M&A resurgence?
- How are valuations shifting across MedTech?
- Who are the most active buyers?
- FAQ
- Key takeaways
- Disclaimer
What is driving the M&A resurgence?
Deal activity accelerated in 2024 and 2025 as interest rate outlooks improved and credit markets stabilized. Strategic plans that had been on hold for over a year were revived. The valuation climate adjusted to a more balanced range, allowing buyers to preserve premium pricing for high-growth technologies while securing fairer deals in mature categories.
- Stability in lending conditions supported transaction confidence
- Backlog of paused strategic initiatives resumed
- Premium multiples maintained in key device markets
- Strong uptake in smaller tuck-in acquisitions for scaling and technology expansion
Mid-market transactions — primarily founder-led MedTech companies with $10 million to $300 million in revenue — are proving to be the most consistent drivers of deal volume. These businesses tend to have solid clinical outcomes, protected intellectual property, and recurring revenue streams suitable for both buy-and-build strategies and strategic portfolio enhancement.
How are valuations shifting across MedTech?
Valuation trends reveal differences between high-growth and mature segments. Categories such as structural heart, peripheral vascular intervention, neurovascular, and niche diagnostics are trading at elevated EV/Revenue and EV/EBITDA multiples. At the same time, areas that surged during pandemic demand have normalized to sustainable historical ranges.
- Premium pricing continues in cardio-intervention and neurovascular segments
- Normalization in formerly overheated pandemic-driven categories
- Wider spreads between companies with strong and weak reimbursement outlooks
- Regulatory certainty and robust clinical data increasingly affect valuation outcomes
Recent DOJ and FTC merger guidelines have added diligence requirements and structural considerations, especially where market concentration is a concern. This has affected deal pacing and in-depth review processes.
Who are the most active buyers?
Leading corporate buyers over the past two years include Johnson & Johnson, Stryker, Boston Scientific, Medtronic, Siemens Healthineers, Abbott, GE HealthCare, Edwards, BD, and Zimmer Biomet. Their strategies vary but center on acquiring adjacent capabilities, rebalancing portfolios, and integrating advanced technologies like AI and surgical robotics.
Private equity activity remains strong in contract manufacturing and specialized MedTech niches. The focus areas for PE include:
- Device contract manufacturing and outsourcing
- Surgical and diagnostic consumables
- MedTech software and data analytics platforms
- Specialized devices with scalable operations
Both buyer groups are acting on well-developed investment theses, showing clear alignment between market direction and acquisition targets.
FAQ
- What size of MedTech companies are attracting the most interest?
Mid-market businesses with $10M to $300M revenue are seeing consistent acquisition demand from both strategics and private equity. - Which MedTech sub-sectors have the highest valuation multiples?
Structural heart, neurovascular intervention, peripheral vascular, and specialized diagnostics continue to command premium multiples. - How are new merger guidelines affecting deals?
Heightened regulatory review is adding diligence steps and influencing deal timelines, particularly in concentrated market segments.
Key takeaways
MedTech M&A markets have entered a more confident phase, supported by stronger credit conditions and resumed strategic projects. High-growth device categories remain valued at a premium, while buyers on both corporate and private equity fronts are moving intentionally toward capabilities that will shape future care delivery. For founders and executives, understanding valuation drivers and aligning with prevailing acquisition strategies is essential for positioning ahead of further market gains.
Disclaimer
This content is for informational purposes only and does not constitute financial advice. Readers should do their own research before making investment or transactional decisions.